Page 14 - Metastatic castration-naive and castration-sensitive prostate cancer: CUA/CUOG

Conclusions

• The last five years has seen a significant change in the treatment

landscape for patients with mCNPC/mCSPC

– These new treatments are life-extending

• All men with mCNPC should be considered for treatments that are

combined with ADT:

– Those with high-risk/high-volume disease should be given systemic therapy

– Those with low-risk/low-volume should be strongly considered for prostate

radiation therapy and/or systemic therapy

ADT: androgen-deprivation therapy; mCNPC: metastatic castration-naive prostate cancer; mCSPC: metastatic
castration-sensitive prostate cancer